8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 15, 2011

REMEDENT, INC.

(Exact name of Registrant as Specified in its Charter)

Nevada (State or Other Jurisdiction of Incorporation) 001-15975 (Commission File Number) 86-0837251 (IRS Employer Identification No.)

BelgiumZuiderlaan 1-3 bus 8, 9000 Ghent, Belgium  (Address of Principal Executive Offices) N/A (Zip Code)

011-329-321-7080

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 2 – Financial Information

Item 2.02  Results of Operations and Financial Condition.

On July 15, 2011, the Company issued a press release reporting its financial results for the year and fourth quarter ended March 31, 2011, and announcing a conference call to discuss the results on Tuesday, July 19, 2011, at 7:00 a.m  Eastern time (10:00 a.m. Pacific time).

A copy of the press release is attached hereto as Exhibit 99.1 and  incorporated herein by reference.

Section  7 – Regulation FD

Item 7.01.  Regulation FD Disclosure

On July 15, 2011, the Company issued a press release reporting  itsfinancial results for the year and quarter ended March 31, 2011, and announcing  conference call to discuss the financial results and plans for the remainder of the fiscal year, including efforts to focus resources on expansion in China, and reduce corporate overhead expenses, on Tuesday, July 19, 2011, at 7:00 a.m  Eastern time (10:00 a.m. Pacific time).

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 – Financial Statements and Exhibits

Item 9.01  Financial Statements and Exhibits.

(d)           Exhibits.

Exhibit No.	Exhibit Description
99.1	Press Release dated July 15, 2011

The information set forth under Items 2.02 and 7.01 of this Form 8-K and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation by reference language in any filing.

Portions of this report constitute “forward-looking statements” defined by federal law.  Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REMEDENT, INC.,
	a Nevada corporation
Dated:   July 15, 2011	By:	/s/ Stephen Ross
		Stephen Ross Chief Financial Officer

3

EX-99.1

Exhibit 99.1

Remedent Reports Fourth Quarter and Year End Results and to

Host a Conference Call at 10 AM EST, Tuesday, July 19, 2011

Gent, Belgium—(marketwire-07/15/2011)-Remedent, Inc. (OTC.BB:REMI-News), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the fourth quarter and for the year ended March 31, 2011 (in US Dollars).

Net sales for the fourth quarter increased 17% to $2.8 million from $2.4 million in the same year ago quarter. The increase in sales is attributable to increased sales in Asia.

Loss from operations in the fourth quarter was a loss of $933,000 compared to a loss of $462,330 in the same year ago quarter.

Net sales for the year increased by $4.25 million 52% to $12.5 million in the year ended March 31, 2011 as compared to $8.25 million of sales in the year ended March 31, 2010. Net loss for the year ended March 31, 2011 was $1.5 million or $ (.08) per share, as compared with a loss of $2.4 million, or $ (0.12) per share for the year ended March 31, 2010.

Cash and Cash equivalents totaled $1.6 million at March 31, 2011 as opposed to $614,000 at March 31, 2010.

Management Commentary:

“Our investment in our Chinese operations continues to exceed our expectations. For the year ended March 31, 2011, Glamsmile Asia generated approximately $850 thousand dollars in net income prior to tax. We anticipate further growth in China as a new fourth studio is expected to open in Wenzhou, China  in September, 2011.

Our net loss for the year was negatively impacted by an impairment loss of $750,000 for Soca Networks Singapore, an investment made in a production facility to produce our Glamsmile veneers. The investment was made in two installments of $375,000 each, with the last payment being made in March 2008. Since management believes that the time-frame for recovery cannot be predicted with any certainty and as a result we took a 100% impairment allowance at year-end. In addition to this, our results were also impacted by the write off of approximately $100,000 for certain patents which are unrelated to our veneer market and current strategic plan.  In addition, our results also reflect a deferred revenue of $475,250 for an advance payment we received for veneers. Upon delivery of the veneers, the cost of goods sold will be recorded and the revenue recognized.

For the remainder of the fiscal year, management intends to focus its efforts and resources on expanding and developing its Chinese operations, where it sees growth and potential. This focus may include changing the name of our entity from Remedent Inc., to Glamsmile Inc., and seeking additional board members who have relevant experience with our business, particularly in the dental market in Asia.  In addition, management intends to focus on reducing current and future corporate overhead expenses, by consolidating some of its operations and repositioning the strategy of its USA and European operations on establishing revenue streams through royalty agreements for its products.

We certainly are looking forward to getting Glamsmile Asia positioned as one of the leading dental brands luxury brands in China as well as the neighboring  nearby other emerging Asian markets” said Guy De Vreese the CEO of Remedent.

Conference Call Information:

Remedent will host a conference call on Tuesday, July 19, 2011 at 10:00 a.m. Eastern Standard Time (7:00 a.m. Pacific Standard Time) to discuss these results and its strategic plans for the future. A question and answer session will follow management’s presentation.

To participate in this call, dial the appropriate number 5-10 minutes prior to the start time.

Date: Tuesday, July 19, 2011

Time: 10:00 a.m. Eastern Standard Time. (7:00 a.m. Pacific Standard Time)

Dial in Number: 1-866-226-1792

A telephone replay of the call will be available until August 15, 2011

Toll Free Replay Number: 1-800-408-3053

Replay Password: 6787766

About Remedent

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. The company serves professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com.

Forward-Looking Statements

Statements in this press release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," "projects," "project," to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent's ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent's business, please refer to the risk factors described in Remedent's filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	For the years ended March 31,
	2011			2010
Net sales	$	12,581,708		$	8,247,940
Cost of sales		3,947,699			4,322,680
Gross profit		8,634,009			3,925,260
Operating Expenses
Research and development		429,244			271,195
Sales and marketing		2,220,686			1,352,260
General and administrative		4,972,982			4,524,324
Depreciation and amortization		779,883			726,499
TOTAL OPERATING EXPENSES		8,402,795			6,874,278
OPERATING INCOME (LOSS)		231,214			(2,949,018	)
NON-OPERATING (EXPENSE) INCOME
Impairment of long-term investments and advances		(750,000	)		—
Warrants issued pursuant to Distribution Agreements		—			(168,238	)
Interest expense		(260,235	)		(171,364	)
Interest income		159,289			170,244
TOTAL OTHER INCOME (EXPENSES)		(850,946	)		(169,358	)
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES		(619,732)			(3,118,376	)
Income tax expense		(220,297	)		(14,242	)
NET INCOME (LOSS)		(840,029)			(3,132,618	)
NET INCOME (LOSS) ATTRIBUTABLE TO NON-CONTROLLING INTERESTS		(707,146)			(782,703	)
NET LOSS ATTRIBUTABLE TO REMEDENT INC. Common Stockholders	$	(1,547,175	)	$	(2,349,915	)
LOSS PER SHARE
Basic and fully diluted	$	(0.08	)	$	(0.12	)
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and fully diluted		19,995,969			19,995,969
Net Loss attributable to Remedent, Inc. common shareholders	$	(1,547,175	)	$	(2,349,915	)
OTHER COMPREHENSIVE INCOME (LOSS):
Foreign currency translation adjustment		(184,890	)		(9,464	)
Total Other Comprehensive loss		(1,732,065	)		(2,359,379	)
LESS: COMPREHENSIVE INCOME ATTRIBUTABLE TO NON-CONTROLLING INTEREST		21,996			7,130
COMPREHENSIVE (LOSS) ATTRIBUTABLE TO REMEDENT, INC. common shareholders	$	(1,710,069	)	$	(2,366,509	)

REMEDENT, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2011			March 31, 2010
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	1,662,520		$	613,466
Accounts receivable, net of allowance for doubtful accounts of $28,975 at March 31, 2011 and $65,845 at March 31, 2010		2,764,651			806,931
Inventories, net		2,164,046			2,161,692
Prepaid expense		762,953			920,487
Total current assets		7,354,170			4,502,576
PROPERTY AND EQUIPMENT, NET		1,401,735			1,735,719
OTHER ASSETS
Long term investments and advances		—			750,000
Patents, net		166,746			246,992
Goodwill		699,635			699,635
Total assets	$	9,622,286		$	7,934,922
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES:
Current portion, long term debt	$	184,679		$	215,489
Line of Credit		2,160,674			674,600
Short term loan		400,000			—
Accounts payable		1,744,253			1,932,684
Accrued liabilities		1,256,148			491,536
Deferred revenue		475,250			—
Due to related parties		95,354			268,484
Total current liabilities		6,316,358			3,582,793
Long term debt less current portion		273,557			425,882
Total liabilities		6,589,915			4,008,675
EQUITY:
Preferred Stock $0.001 par value (10,000,000 shares authorized, none issued and outstanding)		—			—
Common stock, $0.001 par value; (50,000,000 shares authorized, 19,995,969 shares issued and outstanding at March 31, 2011 and March 31, 2010 respectively)		19,996			19,996
Treasury stock, at cost; 723,000 shares outstanding at March 31, 2011 and March 31, 2010 respectively		(831,450	)		(831,450	)
Additional paid-in capital		24,855,883			24,742,201
Accumulated deficit		(21,113,118	)		(19,565,943	)
Accumulated other comprehensive income (loss) (foreign currency translation adjustment)		(834,949	)		(650,059	)
Obligation to issue shares		97,500			97,500
Total Remedent, Inc. stockholders’ equity		2,193,862			3,812,245
Non-controlling interest		838,509			114,002
Total stockholders’ equity		3,032,371			3,926,247
Total liabilities and equity	$	9,622,286		$	7,934,922